Alpha 2.0
Login Register
» Articles » PMID: 27771611

Identification of a FGFR3-TACC3 Fusion in Esophageal Cancer

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2016 Oct 25
PMID 27771611
Citations 5
Authors
T Mizukami
K Sakai
S Naruki
T Taniyama
Y Horie
N Izawa
T Tsuda
T Fujino
N Boku
H Yasuda
T Fukunaga
T Eguchi Nakajima
K Nishio
Affiliations
Soon will be listed here.
Citing Articles

CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo.

Wang Y, Zhu J, Liu S, Sun Z, Wen G, Huang D Onco Targets Ther. 2024; 17:1197-1207.

PMID: 39717713 PMC: 11664097. DOI: 10.2147/OTT.S492659.

Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling.

Nita A, Abraham S, Krejci P, Bosakova M Cells. 2021; 10(6).

PMID: 34207779 PMC: 8227969. DOI: 10.3390/cells10061445.

Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.

Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X Cell Prolif. 2021; 54(4):e13009.

PMID: 33655556 PMC: 8016646. DOI: 10.1111/cpr.13009.

Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma.

Nannapaneni S, Griffith C, Magliocca K, Chen W, Lyu X, Chen Z PLoS One. 2021; 16(2):e0247498.

PMID: 33626078 PMC: 7904228. DOI: 10.1371/journal.pone.0247498.

TACC3 as an independent prognostic marker for solid tumors: a systematic review and meta-analysis.

Wang J, Du S, Fan W, Wang P, Yang W, Yu M Oncotarget. 2017; 8(43):75516-75527.

PMID: 29088887 PMC: 5650442. DOI: 10.18632/oncotarget.20466.